Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001493152-24-036326

← back to feed
Filed
Sep 16, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Sep 16, 2024 4.46M sh
Long Term Debt Q3 2024 · Jul 31, 2024 $3.02M
Long Term Debt Q3 2024 · Oct 31, 2023 $2.95M
Short Term Debt Q3 2024 · Jul 31, 2024 $5.34M
Short Term Debt Q3 2024 · Oct 31, 2023 $480K
Current Liabilities Q3 2024 · Jul 31, 2024 $10.16M
Current Liabilities Q3 2024 · Oct 31, 2023 $4.85M
Total Liabilities Q3 2024 · Jul 31, 2024 $14.13M
Total Liabilities Q3 2024 · Oct 31, 2023 $9.43M
Current Assets Q3 2024 · Jul 31, 2024 $1.93M
Current Assets Q3 2024 · Oct 31, 2023 $3.18M
Total Assets Q3 2024 · Jul 31, 2024 $6.81M
Total Assets Q3 2024 · Oct 31, 2023 $8.34M
Net Income Q3 2024 · Oct 31, 2023 −$5.4M
Net Income Q3 2024 · Jul 31, 2023 −$871.68K
Net Income Q3 2024 · Jul 31, 2023 −$3.48M
Net Income Q3 2024 · Apr 30, 2023 −$1.41M
Net Income Q3 2024 · Jan 31, 2023 −$1.19M
Shares Diluted restated Q3 2024 · Jul 31, 2023 4.43M sh
Shares Diluted restated Q3 2024 · Jul 31, 2023 4.43M sh
Capex Q3 2024 · Jul 31, 2023 $127.16K
Operating Cash Flow Q3 2024 · Jul 31, 2023 −$1.97M
Stockholders Equity Q3 2024 · Jul 31, 2023 $399.54K
Stockholders Equity Q3 2024 · Apr 30, 2023 $885.04K
Stockholders Equity Q3 2024 · Jan 31, 2023 $1.91M
Stockholders Equity Q3 2024 · Oct 31, 2022 $2.84M
Eps Diluted Q3 2024 · Jul 31, 2023 −$0.20
Eps Diluted Q3 2024 · Jul 31, 2023 −$0.78
Eps Basic Q3 2024 · Jul 31, 2023 −$0.20
Eps Basic Q3 2024 · Jul 31, 2023 −$0.78
Sga Expense Q3 2024 · Jul 31, 2023 $1.49M
Sga Expense Q3 2024 · Jul 31, 2023 $4.45M
Rd Expense Q3 2024 · Jul 31, 2023 $33.15K
Rd Expense Q3 2024 · Jul 31, 2023 $106.43K
Operating Income Q3 2024 · Jul 31, 2023 −$1.04M
Operating Income Q3 2024 · Jul 31, 2023 −$3.55M
Gross Profit Q3 2024 · Jul 31, 2023 $480.43K
Gross Profit Q3 2024 · Jul 31, 2023 $1M
Cost Of Revenue Q3 2024 · Jul 31, 2023 $96.82K
Cost Of Revenue Q3 2024 · Jul 31, 2023 $225.96K
Revenue Q3 2024 · Jul 31, 2023 $577.24K
Revenue Q3 2024 · Jul 31, 2023 $1.23M